STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/ Gleevec) 400 mg daily versus dasatinib (Sprycel) 100 mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

Trial Profile

STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/ Gleevec) 400 mg daily versus dasatinib (Sprycel) 100 mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-2
  • Most Recent Events

    • 01 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 14 Jun 2015 Two-year follow-up results presented at the 20th Congress of the European Haematology Association.
    • 15 Mar 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top